Market Overview:
The global myelodysplastic syndrome (MDS) therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of MDS, rising awareness about MDS and its treatment options, and the launch of novel therapies for MDS. The myelodysplastic syndrome (MDS) therapeutics market is segmented on the basis of type into azacitidine, lenalidomide, decitabine, deferasirox, and others. The azacitidine segment is expected to account for the largest share of the global myelodysplastic syndrome (MDS) therapeutics market in 2018. This segment is also projected to grow at a CAGR of 5.9% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to its high efficacy and safety profile compared with other available therapies for MDS patients. On the basis of application, the myelodysplastic syndrome (MDS) therapeutics market is divided into in-patient and out-patient applications.
 Therapeutics Industry Outlook.svg)
Product Definition:
Myelodysplastic Syndrome (MDS) is a group of blood disorders that affect the bone marrow and blood cells. MDS Therapeutics are drugs used to treat patients with Myelodysplastic Syndrome (MDS). The importance of MDS Therapeutics is that they can improve the quality of life for patients with Myelodysplastic Syndrome (MDS).
Azacitidine:
Azacitidine is an antimetabolite and cytotoxic drug used in the treatment of patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms. It is also used as a pre-treatment for these diseases in some instances.
Lenalidomide:
Lenalidomide is a drug that has been licensed by the FDA for the treatment of patients with multiple myeloma and low-risk myelodysplastic syndrome (MDS) who are candidates for radiotherapy or chemotherapy. It is also used in the treatment of acute lymphoblastic leukemia in combination with hydroxyurea. Lenalidomide may be used as monotherapy or combined therapy depending on patient’s response and disease progression.
Application Insights:
In-patient myelodysplastic syndrome application segment dominated the global market in 2017. This can be attributed to the availability of a number of products for use in this population and increasing awareness about MDS treatment options. In addition, factors such as rising prevalence of cancer and increasing geriatric population are expected to boost demand over the forecast period.
The out-patient myelodysplastic syndrome segment is anticipated to witness lucrative growth during the study period owing to an increase in product approvals by regulatory authorities across countries, including Japan, China, India and Australia; Brazil; Argentina; South Africa; Mexico; Spain; Italy among others. For instance, decitabine has been approved by FDA under accelerated approval (AA) program for treating patients with MDS who have received no prior therapy or have progressed after two or more lines of therapy (imatinib).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and increasing healthcare expenditure are some factors responsible for its growth. In addition, rise in awareness about MDS is another factor contributing to its growth. According to NCBI; as of November 2018 there were 1,068 unique publications related to myelodysplasia or MDS disease associated with it PubMed indexed within the last 10 years from PubMed inception (1946).
Asia Pacific is expected to witness lucrative CAGR over the forecast period owing to rising incidence of cancer and other diseases coupled with improving healthcare infrastructure & availability in emerging countries such as China & India. Moreover, growing medical tourism industry due to low treatment cost will also boost regional market growth over the forecast period.
Growth Factors:
- Increasing incidence of myelodysplastic syndrome (MDS)
- Rising demand for better treatment options for myelodysplastic syndrome (MDS)
- Growing awareness about myelodysplastic syndrome (MDS) among people
- Technological advancements in the field of myelodysplastic syndrome (MDS) therapies
- Availability of government funding for research and development activities in the field of myelodysplastic syndrome (MDS)
Scope Of The Report
Report Attributes
Report Details
Report Title
Myelodysplastic Syndrome (MDS) Therapeutics Market Research Report
By Type
Azacitidine, Lenalidomide, Decitabine, Deferasirox, Others
By Application
In-Patient, Out-Patient
By Companies
Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd, Mylan N.V.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Myelodysplastic Syndrome (MDS) Therapeutics Market Report Segments:
The global Myelodysplastic Syndrome (MDS) Therapeutics market is segmented on the basis of:
Types
Azacitidine, Lenalidomide, Decitabine, Deferasirox, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
In-Patient, Out-Patient
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis AG
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Sandoz Inc.
- Dr Reddys Laboratories Limited
- Pharmascience Inc.
- Accord Healthcare Ltd
- Mylan N.V.
 Therapeutics Market Overview.svg)
Highlights of The Myelodysplastic Syndrome (MDS) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
- Others
- By Application:
- In-Patient
- Out-Patient
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myelodysplastic Syndrome (MDS) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myelodysplastic syndrome (MDS) is a rare blood cancer that affects the bone marrow. The disease causes the bone marrow to make too few white blood cells, which can lead to infections and other health problems. Treatment for MDS typically includes chemotherapy and radiation therapy.
Some of the major companies in the myelodysplastic syndrome (mds) therapeutics market are Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd, Mylan N.V..
The myelodysplastic syndrome (mds) therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myelodysplastic Syndrome (MDS) Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Myelodysplastic Syndrome (MDS) Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Myelodysplastic Syndrome (MDS) Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Myelodysplastic Syndrome (MDS) Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Myelodysplastic Syndrome (MDS) Therapeutics Market Size and Y-o-Y Growth
4.5.2 Myelodysplastic Syndrome (MDS) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Azacitidine
5.2.2 Lenalidomide
5.2.3 Decitabine
5.2.4 Deferasirox
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 In-Patient
6.2.2 Out-Patient
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Myelodysplastic Syndrome (MDS) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Azacitidine
9.6.2 Lenalidomide
9.6.3 Decitabine
9.6.4 Deferasirox
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 In-Patient
9.10.2 Out-Patient
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Azacitidine
10.6.2 Lenalidomide
10.6.3 Decitabine
10.6.4 Deferasirox
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 In-Patient
10.10.2 Out-Patient
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Azacitidine
11.6.2 Lenalidomide
11.6.3 Decitabine
11.6.4 Deferasirox
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 In-Patient
11.10.2 Out-Patient
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Azacitidine
12.6.2 Lenalidomide
12.6.3 Decitabine
12.6.4 Deferasirox
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 In-Patient
12.10.2 Out-Patient
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Azacitidine
13.6.2 Lenalidomide
13.6.3 Decitabine
13.6.4 Deferasirox
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 In-Patient
13.10.2 Out-Patient
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Myelodysplastic Syndrome (MDS) Therapeutics Market: Competitive Dashboard
14.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis AG
14.3.2 Celgene Corporation
14.3.3 Otsuka Pharmaceutical Co., Ltd.
14.3.4 Sandoz Inc.
14.3.5 Dr Reddys Laboratories Limited
14.3.6 Pharmascience Inc.
14.3.7 Accord Healthcare Ltd
14.3.8 Mylan N.V.
